NEW YORK – Medical device company Magnolia Medical announced Thursday a collaboration with Cardinal Health to distribute Magnolia's Steripath Gen2 Initial Specimen Diversion Device, which works to reduce blood culture contamination.
Cardinal Health will offer the device to hospitals as a standalone product or as part of a customizable best practice kit, with the goal of reducing false-positive diagnostic results for sepsis from blood contamination.